The safety and effectiveness of lumbar transforaminal injection of sterile amniotic fluid filtrate compared to steroid for lumbosacral radicular pain due to spinal stenosis: a phase I/II double-blinded randomized trial
Pain Medicine · 2026
DOI: 10.1093/pm/pnag048 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, 2026. Verfasst von Zachary L McCormick und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, University of Utah, Salt Lake City, UT, United States. Hauptthemen laut MEDLINE: Spinal Stenosis, Dexamethasone, Amniotic Fluid, Radiculopathy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Utah's Cell Therapy and Regenerative Medicine Program, Skaggs Foundation for Research, University of Utah’s Cell Therapy and Regenerative Medicine Program.
Abstract (Originalsprache)
Background
Radicular symptoms from lumbosacral spinal stenosis (LSS) are commonly managed with conservative measures, including transforaminal epidural steroid injection (TFESI). However, repeated use may cause systemic side effects in some patients. Human amniotic fluid filtrate (hAF), containing anti-inflammatory, neuroprotective, and regenerative factors, has shown therapeutic potential in pre-clinical models and other medical conditions.
Objectives
Compare the safety and effectiveness of transforaminal epidural injections with hAF versus dexamethasone for treating radicular pain from LSS.
Design
Double-blinded, prospective, randomized comparative trial.
Methods
Fifty-eight participants were included, with outcomes assessed at 3 weeks, 6 weeks, 3 months (primary endpoint), and 6 months. Primary outcomes were adverse events (AEs) and proportions of participants reporting ≥50% numerical pain rating scale (NPRS) back and leg pain reductions at 3 months. Secondary outcomes included Oswestry Disability Index (ODI), Swiss Spinal Stenosis Questionnaire (SSSQ), and PROMIS Physical Health Summary (PHS). Linear mixed-effects models evaluated between-group differences while accounting for repeated measures.
Results
At 3 months, a significantly greater proportion of participants receiving dexamethasone achieved ≥50% reductions in back pain (45.8% [95%CI = 27.9%-64.9%] vs. 15.0% [95%CI = 5.2%-36.0%]; P = .050) and leg pain (60.0% [95%CI = 40.7%-76.6%] vs. 25.0% [95%CI = 11.2%-46.9%]; P = .034) compared with hAF. Secondary outcome trends similarly favored dexamethasone at 3 months. Mixed-effects models showed greater improvements to 6-week pain and function scores with dexamethasone relative to hAF. Group AE rates were comparable, and no serious intervention-related AEs occurred.
Conclusion
Dexamethasone demonstrated significantly greater short- and intermediate-term benefits over hAF across multiple clinical outcome domains for radicular pain due to LSS, prompting early trial discontinuation. Trial Registration ClinicalTrials.gov (NCT04537026); September 3, 2020.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physical Medicine and Rehabilitation, University of Utah, Salt Lake City, UT, United States.
- Division of Physical Medicine and Rehabilitation, University of Calgary, Calgary, AB, Canada.
- Vivo Cura Health, Calgary, AB, Canada.
- Cell Therapy and Regenerative Medicine Program, University of Utah School of Medicine, Salt Lake City, UT, United States.
- Department of Orthopedics, University of Utah, Salt Lake City, UT, United States.
ORCID-Profile: Hasan Sen, Amanda N Cooper, Taylor Burnham, Graham Wagner
Förderung
- University of Utah's Cell Therapy and Regenerative Medicine Program
- Skaggs Foundation for Research
- University of Utah’s Cell Therapy and Regenerative Medicine Program
Zitieren
APA
McCormick, Z. L., Sen, H., Cooper, A. N., Conger, A. M., Fogarty, A. E., Glinka Przybysz, A., Burnham, T., Kendall, R., Wagner, G., Hansen, P. A., Pierce, J., Hashimoto, B., Cushman, D. M., & Martin, B. I. (2026). The safety and effectiveness of lumbar transforaminal injection of sterile amniotic fluid filtrate compared to steroid for lumbosacral radicular pain due to spinal stenosis: a phase I/II double-blinded randomized trial. Pain Medicine. https://doi.org/10.1093/pm/pnag048
Vancouver
McCormick ZL, Sen H, Cooper AN, Conger AM, Fogarty AE, Glinka Przybysz A, et al. The safety and effectiveness of lumbar transforaminal injection of sterile amniotic fluid filtrate compared to steroid for lumbosacral radicular pain due to spinal stenosis: a phase I/II double-blinded randomized trial. Pain Medicine. 2026. doi:10.1093/pm/pnag048
BibTeX
@article{McCormick2026,
author = {McCormick, Zachary L and Sen, Hasan and Cooper, Amanda N and Conger, Aaron M and Fogarty, Alexandra E and Glinka Przybysz, Allison and Burnham, Taylor and Kendall, Richard and Wagner, Graham and Hansen, Pamela A and Pierce, Jan and Hashimoto, Brooke and Cushman, Daniel M and Martin, Brook I},
title = {The safety and effectiveness of lumbar transforaminal injection of sterile amniotic fluid filtrate compared to steroid for lumbosacral radicular pain due to spinal stenosis: a phase I/II double-blinded randomized trial},
journal = {Pain Medicine},
year = {2026},
doi = {10.1093/pm/pnag048}
}
EUVIMED